30674

Sigma-Aldrich

Atto 700

BioReagent, suitable for fluorescence, ≥96.0% (HPCE)

MDL number:
NACRES:
NA.32
Pricing and availability is not currently available.

Quality Level

product line

BioReagent

assay

≥96.0% (HPCE)

fluorescence

λex 681 nm; λem 714 nm in 0.1 M phosphate pH 7.0

suitability

suitable for fluorescence

storage temp.

−20°C

General description

Atto 700 is a new label with high molecular absorption (1.2 x 105) and quantum yield (0.25) as well as sufficient Stoke′s shift between excitation and emission maximum. Atto 700 is characterized by high photostability and thermal stability. It is also excellently soluble in water. Due to an insignificant triplet formation rate, it is well suited for single molecule detection applications.

Application

Atto labels have rigid structures that do not show any cis-trans-isomerization. Thus these labels display exceptional intensity with minimal spectral shift on conjugation.
Atto 700 belongs to a new generation of fluorescent labels. The dye is designed for application in the area of life science, e.g. labeling of DNA, RNA or proteins. Characteristic features of the label are strong absorption, high fluorescence quantum yield, excellent thermal and photo-stability, very good water solubility and very little triplet formation. Atto 700 is a zwitterionic dye with a net electrical charge of zero. The fluorescence is efficiently quenched by electron donors like guanine, tryptophan, etc.

Legal Information

This product is for Research use only. In case of intended commercialization, please contact the IP-holder (ATTO-TEC GmbH, Germany) for licensing.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Multicolour single molecule imaging in cells with near infra-red dyes.
Tynan, C.J., et al.
PLoS ONE, 4, e36265-e36265 (2012)
Daniel Riester et al.
Bioorganic & medicinal chemistry letters, 19(13), 3651-3656 (2009-05-22)
Histone deacetylases reside among the most important and novel target classes in oncology. Selective lead structures are intensively developed to improve efficacy and reduce adverse effects. The common assays used so far to identify new lead structures suffer from many...
Judith E Berlier et al.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 51(12), 1699-1712 (2003-11-19)
Amine-reactive N-hydroxysuccinimidyl esters of Alexa Fluor fluorescent dyes with principal absorption maxima at about 555 nm, 633 nm, 647 nm, 660 nm, 680 nm, 700 nm, and 750 nm were conjugated to antibodies and other selected proteins. These conjugates were...
Jan Vogelsang et al.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 8(4), 486-496 (2009-04-02)
The role and interplay of triplet states and radical ion states in single-molecule fluorescence spectroscopy has recently been elaborated providing us with new insights into the photophysics and photobleaching pathways of fluorescent dyes. Adjustment of fluorophore redox properties in combination...
Patricia Haus et al.
Journal of biomolecular screening, 16(10), 1206-1216 (2011-10-27)
Histone deacetylases (HDACs) are important epigenetic factors regulating a variety of vital cellular functions such as cell cycle progression, differentiation, cell migration, and apoptosis. Consequently, HDACs have emerged as promising targets for cancer therapy. The drugability of HDACs has been...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.